Requirement of Plasminogen Binding to Its Cell-Surface Receptor α-Enolase for Efficient Regeneration of Normal and Dystrophic Skeletal Muscle by Díaz Ramos, M. Àngels et al.
Requirement of Plasminogen Binding to Its Cell-Surface
Receptor a-Enolase for Efficient Regeneration of Normal
and Dystrophic Skeletal Muscle
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Abstract
Adult regenerative myogenesis is central for restoring normal tissue structure and function after muscle damage. In muscle
repair after injury, as in severe myopathies, damaged and necrotic fibers are removed by infiltrating inflammatory cells and
then replaced by muscle stem cells or satellite cells, which will fuse to form new myofibers. Extracellular proteolysis
mediated by uPA-generated plasmin plays a critical role in controlling inflammation and satellite-cell-dependent
myogenesis. a-enolase has been described as plasminogen receptor in several cell types, where it acts concentrating
plasmin proteolytic activity on the cell surface. In this study, we investigated whether a-enolase plasminogen receptor plays
a regulatory role during the muscular repair process. Inhibitors of a-enolase/plasminogen binding: MAb11G1 (a monoclonal
antibody against a-enolase) and e-aminocaproic acid, EACA (a lysine analogue) inhibited the myogenic abilities of satellite
cells-derived myoblasts. Furthermore, knockdown of a-enolase decreased myogenic fusion of myoblasts. Injured wild-type
mice and dystrophic mdx mice were also treated with MAb11G1 and EACA. These treatments had negative impacts on
muscle repair impairing satellite cell functions in vitro in agreement with blunted growth of new myofibers in vivo.
Furthermore, both MAb11G1 and EACA treatments impaired adequate inflammatory cell infiltration and promoted
extracellular matrix deposition in vivo, which resulted in persistent degeneration. These results demonstrate the novel
requirement of a-enolase for restoring homeostasis of injured muscle tissue, by controlling the pericellular localization of
plasmin activity.
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Introduction
Degeneration of skeletal muscle can result as a consequence of
injury or disease, as in Duchenne Muscular Dystrophy (DMD), the
most frequent neuromuscular disorder in boys, caused by a defect
in the dystrophin gene [1]. Dystrophin is a large cytoskeletal
protein that forms the dystrophin/glycoprotein complex at the
sarcolemma, which links the cytoskeleton of myofibers to the
extracellular matrix (ECM). The lack of dystrophin disturbs the
assembly of the dystrophin/glycoprotein complex and causes
instability of the muscle membrane, leading to muscle degener-
ation and myofiber loss. Although skeletal muscle has an extensive
ability to regenerate, the permanent damage inflicted by absence
of dystrophin leads to continuous cycles of degeneration,
inflammation and regeneration [2].
Regeneration of adult skeletal muscle depends on muscle
satellite cells, which are found beneath the basal lamina, in a
mitotically quiescent state. In response to injury, satellite cells are
activated, proliferate, and their progeny myoblasts differentiate
into fusion-competent myocytes, which fuse with one another or
with existing myofibers to restore normal tissue architecture [3].
The influx of inflammatory cells is also considered an essential
event of the muscle regeneration process [4]. In addition, efficient
muscle repair also requires the temporary deposition of ECM
components (collagens, proteoglycans and laminin), in order to
stabilize the tissue and serve as scaffold for new fibers. Formation
and degradation of the ECM require the activity of several
proteases, expressed during tissue repair [5]. If the regeneration
process is compromised at any of its different stages, muscle tissue
may be replaced by fibrotic tissue, associated with an impaired
functional capacity.
The proteolytic conversion of the ubiquitous zymogen plasmin-
ogen (Plg) to the active plasmin (Pli) is an extensively used
mechanism for the generation of extracellular proteolytic activity
contributing to ECM degradation and tissue remodeling [6].
Plasminogen conversion into plasmin is exerted by two physio-
logical plasminogen activators (PA): tissue-type (tPA) and uroki-
nase-type (uPA). Plasmin is the major enzyme responsible for the
dissolution of fibrin and most of the components of the ECM.
Plasmin activity is tightly controlled at the level of PAs by
plasminogen activator inhibitors (PAI-1 and PAI-2), and at the
level of plasmin by a2-antiplasmin [6].
Work from numerous groups has clearly demonstrated that the
localization of plasminogen and its activators on the cell surface,
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through association to specific cell membrane receptors, augments
their catalytic efficiency [7,8]. In this field, uPA is recruited to the
cell membrane via a specific receptor (uPAR, CD87) [9]; several
receptors for plasminogen have been described, including a-
enolase [7,10], annexin II [11] and histone H2B [12].
a-enolase is a glycolytic cytoplasmatic enzyme, considered a
multifunctional protein and has been identified as a plasminogen
receptor on the surfaces of several cell types [13]. On the cell
surface, interaction of plasminogen with a-enolase enhances its
activation by PAs, both forms plasminogen and plasmin bind to a-
enolase and this binding protects plasmin from inhibition by a2-
antiplasmin [7,8].
Components of the PA system play important, yet distinct roles
in muscle regeneration after injury, based upon the different
muscle alterations observed in knock-out mice. Our group and
others have shown that while both uPA and plasmin activities are
necessary for skeletal muscle regeneration, tPA activity is
dispensable [14,15]. In contrast, PAI-1-deficient mice showed an
improvement of muscle repair [16]. The important role of the PA
system in muscular dystrophies has increased considerabily in the
last years. For example, genetic loss of uPA exacerbated dystrophy
and reduced muscle function in mdx mice [17]. Our group has
previously demonstrated a role for plasmin in myogenesis in vitro as
well as in skeletal muscle regeneration in vivo [15]. In vertebrates
enolase exist as three different isoforms, a, b and c, being b-
enolase the majoritary form on the adult muscle [18]. b-enolase is
expressed in proliferating adult myoblasts as well as in differen-
tiated myotubes [19]. However, the a-enolase isoform has also
been detected in muscle tissues and muscular cells [20,21].
Furthermore, we have described that a-enolase is up-regulated in
murine myoblasts C2C12 differentiation in vitro, and in muscle
regeneration in vivo [22], raising thus the question of whether
plasminogen receptors may also function in myogenesis and
skeletal regeneration as a mechanism for regulating plasmin
activity.
In order to examine the role of a-enolase in the pericellular
generation of plasmin activity, we produced a monoclonal
antibody, MAb11G1, that specifically blocked a-enolase/plasmin-
ogen binding and inhibited pericellular plasmin generation on
peripheral blood neutrophils and monocytes [23]. In this study, we
have investigated the role of a-enolase as a plasminogen receptor
in muscle regeneration, using a combination of in vivo and in vitro
models. We propose that abrogation of a-enolase/plasminogen
interaction has a direct impact on inflammatory cell infiltration
and satellite-cell-derived myoblasts differentiation.
Materials and Methods
Primary Cell Culture
Muscle Precursor Cells (MPCs) were obtained from muscles of
young (4–8 weeks-old) normal mice as described [24]. MPCs were
maintained on collagen-coated dishes in Ham’s F10 medium
supplemented with 20% fetal bovine serum (FBS) and 5 ng/ml
bFGF (GM, growing medium). To induce differentiation, GM was
replaced by differentiation medium (DM, DMEM supplemented
with 2% horse serum) at myoblast subconfluence. All media were
supplemented with 100 U/ml penicillin and 100 mg/ml strepto-
mycin. Thioglycolate-induced mouse peritoneal macrophages
were obtained as described [25].
Inhibitors
Monoclonal antibodies MAb11G1 and MAb7H8 against a-
enolase, produced in our laboratory [23]; e-aminocaproic acid
(EACA), Sigma; a2-antiplasmin, Loxo GmbH.
Fusion assay
MPCs were cultured in 6-cm plates, 2.56105 cells/plate, in GM
or DM. At the indicated time points, MPCs were fixed in 3.7%
formaldehyde. Non-specific antibody binding was blocked with
TNB buffer (NEN Life Science Products). Cells were then
incubated with an antibody against Embryonic Myosin Heavy
Chain (eMHC, F1652; Developmental Studies Hybridoma Bank)
for 1 h at room temperature, and then incubated in biotinylated
goat anti–mouse antibody (Jackson ImmunoResearch Laborato-
ries). Number of nuclei in eMHC-positive cells was counted and
expressed as a percentage of the total number of nuclei analyzed.
The fusion index or myogenic index was determined by dividing
the number of nuclei within myotubes (4 or more nuclei) by the
total number of nuclei analyzed.
Small interference RNA (siRNA)
siRNA was performed using Lipofectamine RNAiMAX (In-
vitrogen) according to the manufacturer’s protocol. Briefly, 16106
cells were seeded in a 6-wells plate in GM and siRNA were used at
80 nM. The oligonucleotide sequences for the primer pairs used
were: siRNA a-enolase (ENO1), 59-UCA CAG GCU GUU GAG
CAC AUC AAU A-39 and 59- UAU UGA UGU GCU CAA
CAG CCU GUG A-39; siRNA control, 59-GUA AGA CAC GAC
UUA UCG C-39 and 59- GCG AUA AGU CGU GUC UUA C-
39. After 24 hours, the medium was replaced by DM for further
48 hours.
Quantitative Real Time PCR (qRT-PCR)
Total RNA was extracted using UltraspectTM (BioTecx)
isolation system, according to the manufacturer’s instructions.
RNA (1 mg) was reverse-transcribed to cDNA using Sensiscript
enzyme (Invitrogen). Real-time PCR was used to measure specific
mRNAs (Applied Biosystems 7300 Real-Time PCR system).
Amplification mixtures (10 ml) contained the diluted cDNA
sample, 56 LightCycler 480 Syber green Mastermix (Roche)
and primers. Ribosomal protein L32 was used as endogenous
control. Thermal cycling conditions included 10 min at 95uC
before the onset of the PCR cycles, which consisted of 45 cycles
at 95uC for 4 s, 62uC for 30 s and 72uC for 30 s followed by
1 cycle at 95uC for 10 min and 65uC for 1 min. The
oligonucleotide sequences for the primer pairs used were: a-
enolase (ENO 1): 59-AAC CCT GAA GTC ATC CTG CCT
GTC-39 and 59- TTG CCA GAC CTG TAG AAC TCG GAG-
39; myogenin: 59-GGT GTG TAA GAG GAA GTC TGT G-39
and 59-TAG GCG CTC AAT GTA CTG GAT-39; eMHC: 59 –
AAA AGG CCA TCA CTG ACG C -39 and 59- CAG CTC
TCT GAT CCG TGT CTC-39 and ribosomal protein L32: 59-
AAC CCA GAG GAA TTG ACA AC-39 and 59-ATT GTG
GAC CAG GAA CTT GC-39. mRNA expression was calculated
using the DCt method [26].
Mice and induction of muscle regeneration
Mice used were wild type (WT, 9- to 12-week-old) and mdx
dystrophic mice (2- to 8-weeks-old), in C57Bl16 background
(The Jackson Laboratory). All were maintained as a breeding
colony and kept at room temperature with a natural night-day
cycle. All animal experiments were approved by the Catalan
Government Animal Care Committee (permit number 4520).
Before manipulation, WT mice were anesthetized by an
intraperitoneal injection of ketamin/xylacin. Muscular regen-
eration was induced by intramuscular injection of 150 ml of
10 mM cardiotoxin (CTX, Latoxan) in the gastrocnemius
muscle group [17]. Once performed the injury, inhibitors
a-Enolase/Plasminogen Binding on Myogenesis
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were administered by subcutaneous injection every two days,
in the injured region. Morphological and biochemical exam-
inations of gastrocnemius muscles were performed at 4, 10 and
21 days post-injury (d.p.i.). The study in the mdx mice began
when they were 2-weeks-old, before the onset of the disease.
Inhibitors were administrated by intraperitoneal injection
every two days. Mice were sacrificed at 30 and 60 days-old.
Just before the sacrifice, blood was extracted by cardiac
puncture. Diaphragm, tibialis anterioris and gastrocnemius
muscles were analyzed. Six animals were used for each time
point and inhibitor.
Morphometric analysis
Cross-sections (10 mm) were collected from the mid-belly of
muscles and stained with hematoxylin/eosin (H/E) (Sigma) and
with Masson Trichrome (Sigma) using standard protocols. Images
were acquired with an Olympus BX-60 using a Spot camera and
Spot3.2.4 software (Diagnostic Instruments) and 1060.25 NA,
2060.40 NA, and 4060.75 NA objectives (Olympus). The cross-
sectional areas of entire muscles and individual myofibers were
measured using the computer-assisted morphometric measure-
ment ImageJ 1.35J (NIH) program. Muscle degeneration (%) was
determined microscopically and expressed as a percentage of the
total muscle area. Muscle fiber regeneration was determined
microscopically and expressed as the percentage of total muscle
fibers containing central nuclei present in the entire cross section
of the muscle.
Results
a-enolase/plasminogen binding on muscle precursor
cells is required for myogenesis
We first addressed the question of the role of a-enolase on
myogenesis by using primary cultures of muscle precursor cells
(MPCs). a-enolase was expressed in proliferating MPCs cultured
in growth medium (GM – with high serum content), and this
expression was increased as myoblast differentiated and fused in
differentiation medium (DM – with low serum content) (Fig. 1A).
This increase was paralleled by a 2-fold induction of biotinylated-
plasminogen binding to the cell surface after 48 h in DM (see
Materials and Methods S1 and Fig. 1B). In the presence of
440 nM MAb11G1 (a monoclonal antibody against a-enolase,
which selectively inhibits the a-enolase/plasminogen interaction)
or 100 mM EACA (e-aminocaproic acid, a lysine analogue that
inhibits the capacity of plasminogen to bind to the cell surface
through its Lysine Binding Sites), plasminogen binding to the cell
surface was completely abolished (Fig. 1B), demonstrating the
specificity of a-enolase in the plasminogen-binding to the MPCs
surface.
We next used these inhibitors to assess whether the role of
plasmin(ogen) in myogenesis is dependent on its capacity to
associate to the cell surface. When MPCs were cultured under DM
for 48 h, the addition of MAb11G1 or EACA, produced an
important decrease in the expression of the differentiation-specific
marker myogenin (Fig. 1C). Furthermore, an immunocytochem-
ical assay (Fig. 2), using an antibody to embryonic Myosin Heavy
Figure 1. a-enolase expression and biotinylated-plasminogen binding are up-regulated in MPCs undergoing differentiation. A. a-
enolase and myogenin expression on MPCs in Growing Medium (GM) and in Differentiation Medium (DM) for 48 hours. B. Byotinylated-plasminogen
(B-Plg) binding to MPCs on GM and after 24 h on DM, in the presence of MAb11G1 and EACA. Results are expressed as a percentage of total
biotinylated-plasminogen binding in control cells. Results are the mean +/2 SEM (error bars) of three different experiments. ** P,0.005 versus B-Plg
in GM, and *** P,0.005 versus B-Plg in DM. C. Expression of myogenin in differentiated MPCs in presence of MAb11G1 and EACA. A representative
image of triplicates is shown.
doi:10.1371/journal.pone.0050477.g001
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Chain (eMHC) to stain differentiated myocytes/myotubes dem-
onstrated that treatment with MAb11G1 and EACA inhibited the
differentiation ratio by 46.9% and 41.05%, respectively, after 72 h
in DM, compared to control cells (Fig. 2A and 2B). Myotube
formation was also severely impaired by inhibition of a-enolase/
plasminogen binding (Fig. 2A and 2C). At 72 h in DM, MAb11G1
and EACA inhibited the fusion index (polynucleated myotubes
containing more of 4 nuclei), respectively by 82.59% and 86.97%.
Furthermore, the addition of 100 nM a2-antiplasmin, the
physiological inhibitor of plasmin, produced no inhibition of the
differentiation or fusion ratio. The lack of inhibitory abilities of a2-
antiplasmin is consistent through it is described that once plasmin
is bound to its receptor, it remains protected against its inhibitors
[7,8]. These results suggest that plasmin activity needs to be
pericellularly concentrated through a-enolase association for
myogenic differentiation and fusion to occur efficiently; indeed,
interference with this association severely compromised both
myogenic processes.
Next, MPCs were depleted of a-enolase by siRNA. Twenty four
hours after transfection of 80 nM a-enolase specific siRNA
duplexes, cells were cultured in differentiation conditions for
different times. a-enolase expression was markedly reduced,
compared with control siRNA (Fig. 3A). Depletion of a-enolase
induced a decrease of myogenic fusion, with a reduced number of
polynucleated myotubes and formation of smaller myotubes
(Fig. 3B). Immunocytochemical staining of eMHC showed an
inhibition of the fusion index (polynucleated myotybes) of 55.8%
in a-enolase silenced MPCs after 48 hours of differentiation
(Fig. 3C). Furthermore, expression of myogenic markers as
myogenin and eMHC were reduced by 40.3% and 39.9%
respectively (Fig. 3D) in a-enolase depleted MPCs, indicating that
the myogenic ability of these cells was significatively reduced.
Therefore, a-enolase expression is necessary for myogenic fusion
of MPCs.
Expansion of the myoblast population and further migration
prior to their differentiation and fusion are critical steps in the
regeneration of myofibers after injury. As shown in Fig. 4A,
MAb11G1 induced a small but significative inhibiton on MPCs
proliferation (15.6% inhibition), whilst the EACA inhibitory effect
was more important (30.54%). Both MAb11G1 and EACA
inhibited MPCs migration significatively (Fig. 4B). Altogether,
these results indicate that a-enolase/plasminogen binding is
critically required for satellite cell-derived myoblast proliferation,
migration, differentiation and fusion.
Figure 2. Inhibitors of a-enolase/plasminogen binding block myogenic differentiation and fusion. A. Immunocytochemical staining for
eMHC of MPCs in DM in the presence of MAb11G1, EACA and a2-antiplasmin. B. Quantification of the Differentiation ratio (nu eMHC positive cells/
total cells). C. Quantification of the Fusion ratio (nu eMHC positive cells fused in a myotube .4 nuclei/total cells) or Myogenic Index. Results are mean
+/2 SEM (error bars). ** P,0.005. Experiments were performed in triplicates.
doi:10.1371/journal.pone.0050477.g002
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Selective interference of a-enolase/plasminogen
association blunts muscle regeneration in vivo
Knowing that the plasminogen-deficient mice showed a muscle
regeneration defect [15], that a-enolase expression increases in
regenerating muscle [22] and our demonstration that myoblasts
require cell-surface-associated plasminogen for efficient myogen-
esis in vitro, we have investigated the role of a-enolase as a
plasminogen receptor in muscle repair in vivo. The inhibitors
described above were used in an in vivo model of injury-induced
muscle regeneration by cardiotoxin (CTX) injection in the
posterior limbs of 2-month-old mice. Inhibitors (440 nM
MAb11G1, 100 mM EACA and physiologic serum used as
control) were injected periodically (every 2 days) by subcutaneous
injection (s.c.) in the injured hind-limbs, and regeneration
analyzed at 4, 10 and 21 days post-injury (d.p.i.). Plasmin activity
in muscle extracts at 4 d.p.i showed a 2.5-fold increase, compared
to non-injured muscle, and was significatively decreased in
inhibitors-treated mice (Fig. 5B). Histological analysis of injured
muscles at 4 d.p.i. evidenced abundant myofiber necrosis and a
highly disorganized tissue structure, irrespectively of the treatment
(Fig. 5A). At 10 d.p.i. necrotic myofibers had been efficiently
removed in control animals, while regeneration was well
Figure 3. Knockdown of a-enolase by siRNA reduces MPCs differentiation. A. qRT-PCR to determine the relative mRNA quantity of a-
enolase after siRNA transfection. B. Immunocytochemical staining for eMHC of MPCs transfected with a-enolase siRNA or control siRNA, on GM and
DM at 24 and 48 hours. C. Quantification of the Fusion ratio (nu eMHC positive cells fused in a myotube .4 nuclei/total cells) or Myogenic Index. **
P,0.005. D. qRT-PCR to determine relative mRNA quantity of the genes for myogenin and eMHC. Ribosomal protein L32 mRNA levels were used for
normalization. ** P,0.01, *** P,0.005. Results are the mean +/2 SEM (error bars) of three different experiments.
doi:10.1371/journal.pone.0050477.g003
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advanced, as indicated by the presence of small newly-formed
myofibers with central nuclei (which identifies fibers undergoing
regeneration). In contrast, muscles treated with MAb11G1 and
EACA showed a highly disorganized architecture, with prominent
edema, and fibrotic deposits within the enlarged intercellular space
separating necrotic myofibers. At 21 d.p.i. control muscles showed
well organized tissue architecture, characterized by large centrally-
nucleated fibers. In contrast muscles treated with MAb11G1 and
EACA still presented large necrotic areas, with high density of
mononucleated cell infiltrates, and very small centrally-nuclei
myofibers. In particular, at 21 d.p.i. treatment with MAb11G1
and EACA produced a 6.5-fold increase of the degeneration
muscle area (Fig. 5C). A significant decrease of regeneration, as
shown by the number of central nuclei fiber (CNF), and a decrease
of the mean size of the myofibers (Fig. 5C) were observed.
Treatment with MAb7H8, as isotype control, had no effect on the
repair process (data not shown). Furthermore, a strong collagen
accumulation in the muscle ECM, evidenced by trichrome
staining, was found in muscles treated with MAb11G1 and
EACA, at 10 and 21 d.p.i., while it was reduced in control mice at
10 d.p.i. and completely absent at 21 d.p.i. (Fig. 5E), suggesting an
important role of the a-enolase/plasminogen binding in degrada-
tion of the transient ECM of injured muscle. Conversely,
myogenin expression was reduced in extracts of mice treated with
both inhibitors, when compared to control mice (Fig. 5D), whilst
a-enolase expression was not affected. Thus, a-enolase/plasmin-
ogen interaction is required for the efficiency of the muscle
regeneration process. b-enolase, the muscle-specific enolase
isoform was also analyzed (Fig. 5D), and its expression remained
unaltered in MAb11G1-treated mice and a slight decrease was
observed in EACA-treated mice at 21 d.p.i.
Small but strongly expressing eMHC positive-fibers were
present in MAb11G1- and EACA-treated mice at large stages
after injury (10 d.p.i.), indicating a delayed myotube formation in
mice treated with a-enolase/plasminogen binding inhibitors
(Fig. 6). Furthermore, desmin (a marker for myoblasts and early
stage myotubes) remained present in small fibers of MAb11G1-
and EACA-treated mice, demonstrating the existence of more
immature myofibers (Fig. 6). These results indicate that immature
myofibers accumulate in the regenerating tissues, suggesting that
a-enolase/plasminogen binding is necessary for the correct
maturation of satellite cell-derived myoblasts.
a-enolase/plasminogen binding is required for
inflammatory cell infiltration in cardiotoxin-injured
muscle
Although the impaired myogenic functions upon inhibition of
the a-enolase/plasminogen axis could underlie the reduced
growth of regenerating myofibers, they could not account for the
persistence of necrotic infiltrates and degeneration in the treated
muscles. Blood-borne monocyte-macrophages are recruited after
injury to skeletal muscle during the inflammatory phase, that play
a major role in the phagocytosis of tissue debris after muscel injury
[27]. Furthermore, it has been previously shown that uPA- and
plasminogen-deficient mice show an importatn decrease of the
inflammatory response after muscle injury [14,15]. Recently, a-
enolase has been shown to promote plasminogen-mediated
recruitment of monocytes to the acutely inflamed lung [28]; and
contribute to peritoneal macrophage recruitment in response to
thioglycolate [29]. Thus, we reasoned that a functional a-enolase/
plasminogen axis might mediate the inflammatory response in
damaged muscle. Accordingly, we analyzed the effects of
MAb11G1 and EACA on the recruitment of neutrophils, T
lymphocytes and macrophages to the dystrophic muscles, by
immunofluorescency using specific antibodies for each type of cell.
The number of neutrophils, lymphocytes and macrophages
present in the injured muscles was reduced significativelly by
MAb11G1 and EACA treatment (Fig. 7A, 7B and 7C). Consistent
with these in vivo results, MAb11G1 and EACA also inhibited
migration of freshly isolated primary macrophages in Transwell
assays, indicating that macrophage migration depends on a-
enolase/plasmin(ogen) binding and activity (Fig. 7D).
Selective interference of a-enolase/plasminogen binding
exacerbates muscular dystrophy in mdx mice
It was important to analyze if the a-enolase/plasminogen axis
might be functional in a muscular disease context, such as
Duchenne muscular dystrophy (DMD), which courses with
persistent tissue degeneration and fibrosis. We have previously
shown an increase of a -enolase expression in muscle extracts of
mdx mice (the most widely used animal model of DMD) when
compared to WT mice [22]. Accordingly, we analyzed the effect of
the inhibitors of a-enolase/plasminogen binding in the dystrophy
progression in mdx mice. The inhibitors (800 nM MAb11G,
200 mM EACA), or physiologic serum, were injected periodically
(every 2 days) intraperitoneally (i.p.). The treatment was initiated
in 15 days-old mdx mice (before the onset of the disease), and was
maintained until mice were 30 and 60 days old (during the peak of
disease). At 30 days of age (treated with inhibitors for 15 days),
Figure 4. Inhibitors of a-enolase/plasminogen binding inhibits
MPCs proliferation and migration. A. Proliferation of MPCs in the
presence of MAb11G1 or EACA by the MTT proliferation assay. Results
are mean +/2 SEM (error bars) of quadriplicates. * P,0.01. B. MPCs
migration in Transwells chambers, in the presence of MAb11G1 or
EACA. Results are expressed as a percentage of control MPCs migration.
Results are mean +/2 SEM (error bars) of three different experiments. **
P,0.05.
doi:10.1371/journal.pone.0050477.g004
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Figure 5. Inhibitors of a-enolase/plasminogen binding impede skeletal muscle regeneration after injury. A. Hematoxylin/eosin staining
of cross-sections of gastrocnemius muscles of mice treated with inhibitors (MAb11G1, EACA or control) at different days post injury (d.p.i.) B. Plasmin
specific activity (S.A.) of gastrocnemius muscle extracts, expressed as mOD/min/mg protein, as mean +/2 SEM (error bars), * P,0.01. C. Percentage of
degeneration area, percentage of central nucleated fibers (CNF) and mean fiber size of inhibitors-treated mice at 21 d.p.i., mean +/2 SEM (error bars),
** P,0.005, * P,0.01. D. Western blotting of myogenin, a-enolase and b-enolase protein in tibialis anterioris muscle lysates. A representative image
of triplicates is shown. Densitometric quantification of protein levels normalized with respect to a-tubulin is reported in the graphical diagrams. E.
Trichrome staining for collagen deposits in gastrocnemius muscles, treated with the different inhibitors. Bars, 50 mm. n = 6 animals per group.
doi:10.1371/journal.pone.0050477.g005
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obvious signs of myodystrophy were detectable in all treated mice,
with disorganization of the muscle structure, presence of necrotic
areas, inflammatory infiltrates and centrally-nucleated myofibers,
indicating ongoing degeneration/regeneration processes (Fig. 8A).
However, MAb11G1- and EACA-treated mice suffered a much
more severe dystrophinopathy, characterized by an extensive
myofiber degeneration and necrosis and increased presence of
cellular infiltrates, compared to control mice. These differences
were even more striking in 60 days-old mice (treated for 45 days).
MAb11G1 and EACA treatment on mice of 60 days induced a 7-
fold increase of the degenerating muscle area, approximately
(Fig. 8C). Indeed, a decrease in regenerating fibers (CNF) and a
decrease of fiber size were observed on MAb11G1 and EACA
treated mice (Fig. 8C). The same effect of the inhibitors was even
more evident in the diaphragm, considered the more affected
muscle in the mdx mice (Fig. 8A). Compared to control mice,
diaphragms of MAb11G1- and EACA-treated mice showed larger
necrotic areas containing mononucleated cells and degenerating
myofibers. Plasmin activity in mdx gastrocnemius muscles extracts
showed a 2.8-fold increase, compared to WT muscles and was
significativelly reduced in the inhibitors-treated mice (Fig. 8B).
The expression of the myogenic marker myogenin in
MAb11G1- and EACA-treated mice was lower than in control
mice, corroborating an impairment of the regeneration process
(Fig. 8E). In contrast, no changes were observed in a-enolase
expression, indicating that the observed effects are due to a-
enolase function and not to a-enolase expression. No changes on
b-enolase expression were observed in all treated mice (Fig. 8E).
Furthermore, treatment with MAb11G1 and EACA produced an
increase in collagen accumulation in dystrophic muscles, com-
pared to control-treated mice (Fig. 8D).
Muscular creatine kinase (CK) expression is usually restricted to
muscle. Upon sarcolemmal damage, CK muscular content is
released to the blood stream, constituting a widely used biomarker
of muscle damage [2]. Serum CK levels in the mdx mice were twice
the levels in wild type mice and this value was duplicated and
triplicated in MAb11G1- and EACA-treated mice, respectively,
indicating that both inhibitors increased muscle damage in mdx
mice (Fig. 8F).
Trying to define the identity of the mononucleated cells
accumulated in the mdx degenerating muscles, an immunostaining
of eMHC, a marker of myogenic differentiation, was performed.
Figure 6. Inhibitors of a-enolase/plasminogen binding affect nascent myofibers (eMHC positive or desmin positive) into the
damaged muscle. Serial cross-sections of gastrocnemious muscles at 4 and 10 days after cardiotoxin-induced injury were immunostained for eMHC
and desmin. Representative images are shown. Bars, 50 mm. n = 3 animals per group.
doi:10.1371/journal.pone.0050477.g006
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As shown in Figure 9A, strongly expressing eMHC fibers were
observed in degeneration areas, charecterized by an accumulation
of mononucleated cells, indicating that myogenic differentiation
was taking place. MAb11G1- and EACA-treated mice showed an
increase of mononucleated eMHC-positive cells, suggesting that
the inhibitors treatment compromised the fusion process, in
coincidence with the inhibition of myogenic fusion observed in
muscle precursor cells (Fig. 2). Furthermore, eMHC expression
was reduced in the inhibitors treated muscles, indicating that the
myogenic fusion was compromised in these mice (Fig. 9B).
These results show that inhibition of a-enolase/plasminogen
binding aggravates disease progression in dystrophic mdx mice.
a-enolase/plasminogen binding is required for
inflammatory cell infiltration in mdx dystrophic muscle
Muscle dystrophy is characterized by sustained levels of
inflammatory cell infiltrates, particularly, neutrophils, macrophag-
es and T cells [4,17]. Recently uPA-mediated plasmin activity has
been shown to be necessary to mount a proficient inflammatory
response in mdx degenerating muscle [17]. Accordingly, we
analyzed the effects of MAb11G1 and EACA on the recruitment
of neutrophils, T lymphocytes and macrophages to the dystrophic
muscles, by immunofluorescency using specific antibodies for each
type of cell. The number of neutrophils, lymphocytes and
macrophages present in dystrophic muscles was reduced signifi-
cativelly by MAb11G1 and EACA treatment (Fig. 10). These
results show that the recruitment of the major inflammatory cell
types to dystrophic muscle was reduced by inhibition of a-enolase/
plasminogen association.
Discussion
Using genetically modified mice for uPA and plasminogen, we
and others have shown that loss of uPA-mediated plasmin activity
blunts muscle repair in vivo [14,15,17,30]. However, whether
plasmin activity requires cell-surface association for efficient
muscle recovery, and in particular whether a-enolase functions
as a cellular plasmin(ogen) receptor in this process, remained
unknown. In this work, we demonstrate that a-enolase/plasmin-
ogen association regulates two timely-coupled processes in injured
muscle: first, the recruitment of inflammatory cells for the
resolution of tissue damage and, second, satellite-cell-dependent
new myofiber formation.
Mice treated with inhibitors of a-enolase/plasminogen binding
(MAb11G1 and EACA) showed an important defect in muscle
Figure 7. Inhibitors of a-enolase/plasminogen binding affect inflammatory cell recruitment to the damaged muscle.
Immunohistochemical analysis of A, neutrophils (Ly-6G positive cells), B, lymphocytes (CD2 positive cells), and C, macrophages (F4/80 positive
cells) in the cardiotoxin-injured gastrocnemius muscles at 4 and 10 days post injury. Results are expressed as a percentage of positive cells in the
muscles of control- mice. n = 4 animals per group. D. Peritoneal macrophages migration in Transwells chambers, in the presence of inhibitors. Results
are mean +/2 SEM (error bars). ** P,0.01, *** P,0.005.
doi:10.1371/journal.pone.0050477.g007
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regeneration, reminiscent of that observed in plasminogen-
deficient mice and uPA-deficient mice [14,15]. Furthermore,
treatment with MAb11G1 and EACA aggravated myodystrophy
in mdx mice, resembling the uPA-deficient mdx mice [17], which
lacked plasmin activity, reinforcing the idea that inhibition of
plasminogen binding to a-enolase impairs functional plasmin
activity, necessary for maintaining muscle tissue homeostasis after
damage.
Our results demonstrate that treatment with MAb11G1 and
EACA affected several mechanisms in injured and dystrophic
muscle. First, after a myotraumatism, an invasion of the damaged
tissue by inflammatory cells is one of the first steps of the
regeneration process, to degrade cellular debris and necrotic tissue,
and to provide the initial cues for the subsequent proliferation,
differentiation and fusion of satellite cells. Our results show a
reduced recruitment of neutrophils, lymphocytes and macrophag-
es to the dystrophic muscle of MAb11G1 and EACA-treated mdx
mice. The same results were obtained in cardiotoxin-injured
muscles. Thus, plasmin activity associated to the cell surface
appears necessary for inflammatory cell recruitment to damaged
muscle. Consistent with the impaired inflammatory response, we
found an increased and persistent muscular degeneration in mice
treated with a-enolase/plasminogen interaction inhibitors, prob-
ably due to the inability of the inflammatory cells, particularly
macrophages, to phagocytose the necrotic tissue. Since uPA-
mediated plasmin activity was recently shown to be necessary for a
proficient inflammatory response in degenerating muscle [17], our
results support the hypothesis that this proteolytic plasmin activity
needs to be a-enolase associated to the surface of inflammatory
cells to allow them to penetrate the damage muscle. Unresolved
myofiber debris after MAb11G1 and EACA treatments was also
accompanied by accumulation of intramuscular collagen deposits,
which further contributed to the persistence of muscle degener-
ation when plasmin association to a-enolase was impaired.
Secondly, our results demonstrate that treatment with
MAb11G1 and EACA directly affected injury-induced new
myofiber formation in vivo as well as myogenesis in vitro. We
found that satellite cell-derived myoblasts (i.e. MPCs) bound
specifically plasminogen to the cell surface in an a-enolase
dependent manner, and this binding increased during myo-
genic differentiation. This association was critical for myogen-
esis, since MAb11G1 and EACA inhibited satellite cell
migration, proliferation, differentiation and fusion in vitro. In
addition, down-regulation of a-enolase expression by siRNA
reduced the size and number of myotubes and the expression
of myogenic factors. Furthermore, an increase of differentiated
(eMHC positive cells) but not fused cells were detected on
MAb11G1 and EACA treated mdx muscles and injured
muscles, suggesting that myogenic fusion was also impaired
in vivo. These results demonstrate that plasmin activity is
necessary for myogenesis, but, importantly, this activity needs
to be cell-membrane associated. Our conclusions on the
requirement for a-enolase-plasmin association for satellite
cell-dependent myogenesis in vitro and in vivo are consistent
with the impaired myogenic behaviour of myoblasts with
selective interference with uPA and plasmin [14,15,31].
Expression of b-enolase was detected in both models of muscle
regeneration analyzed, and it was unchanged upon the
Figure 8. Inhibitors of a-enolase/plasminogen binding aggravate the myodystrophy of mdx mice. A. Hematoxylin/eosin staining of
cross-sections of gastrocnemius muscles and diaphragms of mdx mice treated with the inhibitors (MAb11G1, EACA or control), until 30 and 60 days of
age. B. Plasmin specific activity (S.A.) of gastrocnemius muscle extracts of treated-mice, represented as mean +/2 SEM (error bars), * P,0.005. C.
Percentage of degeneration area, percentage of central nuclei fibers (CNF) and frequency distribution of fiber size in gastrocnemius muscle of 60 day-
old mice. ** P,0.005, * P,0.01. D. Trichrome staining of cross-sections of gastrocnemius muscles of mdx mice. E. Western blotting of myogenin, a-
enolase and b-enolase protein in tibialis anterioris muscle lysates of mice treated or not with the indicated inhibitors. A representative image is
shown. Densitometric quantification of protein levels normalized with respect to a-tubulin is reported in the graphical diagram. F. Creatine kinase
levels in serum from 60 day-old mice. ** P,0.005. Bars, 50 mm. n = 6 animals per group.
doi:10.1371/journal.pone.0050477.g008
Figure 9. Inhibitors of a-enolase/plasminogen binding affect nascent myofibers (eMHC positive) to the damaged muscle. A. Serial
cross-sections of gastrocnemious muscles of 60 days-old mdx mice were immunostained for eMHC or hematoxylin/eosin stained. Representative
images are shown. Arrows indicate non-fused eMHC-positive cells. Bars, 50 mm. n = 4 animals per group. B. Western blotting of eMHC of
gastrocnemius muscle lysates. A representative image of triplicates is shown.
doi:10.1371/journal.pone.0050477.g009
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inhibitory treatment. The specificity of MAb11G1 on inhibing
the plasminogen binding to a-enolase isoform and the decrease
of myogenic fusion produced by knocking-down of a-enolase
suggest that this is the isoform responsible of the effects
observed on myogenesis.
Altogether, our findings show that treatment of mdx mice
and cardiotoxin-injured muscles with inhibitors of a-enolase/
plasminogen binding exacerbate muscle degeneration by both:
inhibition of inflammatory cell recruitment and removal of
necrotic tissue, and stimulation of collagen deposition. Thus it
promotes the persistence of muscle degeneration, while inhibits
muscle regeneration. In the mdx mice continous cycles of
degeneration/regeneration and fibrosis development, coupled
to attenuated satellite cell functions, are some of the important
pathological causes of the progressive dysfunction and weak-
ness in DMD patients [1]. Our results show that a-enolase/
plasminogen interaction critically regulates these processes in
the mdx mouse.
The work presented here shows that a-enolase is responsible of
plasminogen/plasmin activity associated to the surface of critical
regulatory cell types for muscular remodeling. Proteolysis associ-
ated to the cell surface is a usual mechanism in several
physiological processes involving tissue remodeling. uPAR, the
receptor for the urokinase-plasminogen receptor, concentrates
urokinase-mediated plasmin generation on the cell surface,
directing cell migration, adhesion and proliferation [9]. However,
loss of uPAR in vivo neither affect the skeletal muscle degenera-
tion/regeneration nor impair inflammatory recruitment; in
addition, uPAR was not necessary for efficient myoblast differen-
tiation and fusion in vitro [17,32], indicating that uPAR is
dispensable for efficient muscle repair. This reinforces the idea
that a-enolase is the main functional receptor that concentrates
proteolytic plasminogen activity on the cell surface during muscle
tissue regeneration.
a-enolase has been described as plasmin(ogen) receptor in
several cell types [7,8], although the mechanism by which it is
associated to the cell surface remains unknown, a characteristic
shared with other described receptors for plasminogen as
annexin II [11] and histone H2B [12]. Several post-transla-
tional modifications of a-enolase as phosphorylation, acetyla-
tion and methylation have been identified. For instance, an
increase of acetylated lysines and methylated aspartic acid and
glutamic acid residues of a-enolase were found in pancreatic
ductal adenocarcinoma cells, compared to normal pancreatic
duct cells [33]. Post-translational modifications of a-enolase
have also been associated with autoimmunity to a-enolase in
rheumatoid arthritis [34,35]. However it remains to be
determined how the phosphorylation, acetylation or methyla-
tion of a-enolase can affect its catalytic activity, localization on
the cell surface or association with other proteins. Investigation
of these modifications patterns in muscle regeneration and
myodystrophies will provide insights into the role of a-enolase
as plasminogen receptor in pathophysiological processes.
Other than its role in concentrating plasmin activity on the cell
surface, the question of how a-enolase/plasminogen association
affects muscle cells differentiation and migration remains still
ongoing. The ability of plasminogen to induce intracellular
signaling pathways activation has been described on several cell
types [36–38]. DeSousa et al. have shown that plasmin(ogen)
binding induce c-fos, egr-1 and a-enolase expression via the
MEK/Erk pathway in fibroblasts and [39,40]. We have also
demonstrated that plasmin binding induce the activation of
PI3Kinase and MEK/Erk pathways on muscle cells (Roig-
Borrellas, unpublished results), through this issue remains to be
further investigated.
Up-regulation of a-enolase has been described in several types
of cancer, autoimmune diseases like rheumatoid arthritis and
Alzheimer’s disease [13,41]. Recently, a proteomic meta-analysis
of differently expressed 4.700 proteins, identified a-enolase as the
first protein differentially expressed in mice and the second in
human pathologies [42], suggesting that a-enolase could be
considered as a marker of pathological stress in a high number of
diseases. It is tempting to speculate than in many of these
pathologies, a-enolase could exert one of its multiple functions,
mainly as a plasminogen receptor, focalizing plasmin activity on
the cell membrane and promoting ECM degradation/remodel-
ing. The key role of plasminogen binding to a-enolase in
myogenesis and muscle regeneration shown here constitutes a
first exemple.
In summary, this study highlights the relevance of focalized
pericellular proteolysis in tissue repair, and renders a-enolase/
plasminogen association as a novel selective target for therapeutic
interventions in muscle pathologies.
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Figure 10. Inhibitors of a-enolase/plasminogen binding affect inflammatory cell recruitment to the damaged muscle.
Immunohistochemical analysis of A, neutrophils (Ly-6G positive cells), B, lymphocytes (CD2 positive cells), and C, macrophages (F4/80 positive
cells) in the gastrocnemius muscles of 60 days-old mdx mice. Results are expressed as a percentage of positive cells in the muscles of control- mice.
n = 6 animals per group. ** P,0.005.
doi:10.1371/journal.pone.0050477.g010
a-Enolase/Plasminogen Binding on Myogenesis
PLOS ONE | www.plosone.org 12 December 2012 | Volume 7 | Issue 12 | e50477
Acknowledgments
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